Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Edesa Biotech, Inc. Director's Dealing 2023

Jul 21, 2023

35006_dirs_2023-07-21_2870499e-da74-4cf8-863d-35e93600e033.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edesa Biotech, Inc. (EDSA)
CIK: 0001540159
Period of Report: 2023-07-20

Reporting Person: MacDonald Sean Arthur (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2023-07-20 Share Option (right to buy) $0.8277 A 20000 Acquired 2023-07-20 Common Shares (20000) Direct

Footnotes

F1: This option vests monthly in equal proportions over 12 months beginning on the date of grant.